<div id="readability-page-1"><div>RNS Number : 4790A Citadel Group 23 September 2025 Ap27FORM 8.3IRISH TAKEOVER PANELOPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVERRULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE1. KEY INFORMATION<div><table><tbody><tr><td>(a) Full name of discloser</td><td>Citadel Group</td></tr><tr><td>(b) Owner or controller of interests and short positions disclosed, if different from 1(a)The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.</td><td>N/A</td></tr><tr><td>(c) Name of offeror/offeree in relation to whose relevant securities this form relatesUse a separate form for each offeror/offeree</td><td>MURAL ONCOLOGY PLC</td></tr><tr><td>(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree (Note 1)</td><td>N/A</td></tr><tr><td>(e) Date position held/dealing undertakenFor an opening position disclosure, state the latest practicable date prior to the disclosure</td><td>22 September 2025</td></tr><tr><td>(f) In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer?If it is a cash offer or possible cash offer, state &#34;N/A&#34;</td><td>N/A</td></tr></tbody></table></div>2. INTERESTS AND SHORT POSITIONSIf there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.Ap28Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)(Note 2)<div><table><tbody><tr><td>Class of relevant security (Note 3)</td><td colspan="4">Common Stock ISIN IE000LK2BOB4$0.01 ordinary shares</td></tr><tr><td rowspan="2"></td><td colspan="2">Interests</td><td colspan="2">Short positions</td></tr><tr><td>Number</td><td>%</td><td>Number</td><td>%</td></tr><tr><td>(1) Relevant securities owned and/or controlled</td><td>255,172</td><td>1.47</td><td>0</td><td>0.00</td></tr><tr><td>(2) Cash-settled derivatives</td><td>0</td><td>0.00</td><td>0</td><td>0.00</td></tr><tr><td>(3) Stock-settled derivatives (including options) and agreements to purchase/ sell</td><td>13,400</td><td>0.07</td><td>183,300</td><td>1.05</td></tr><tr><td>Total</td><td>268,572</td><td>1.55</td><td>183,300</td><td>1.05</td></tr></tbody></table></div>All interests and all short positions should be disclosed.Details of options including rights to subscribe for new securities and any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8.3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE (Note 4)Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.The currency of all prices and other monetary amounts should be stated.(a) Purchases and sales<div><table><tbody><tr><td>Class of relevantsecurity</td><td>Purchase/sale</td><td>Number ofsecurities</td><td>Price per unit (Note 5)</td></tr><tr><td> Common</td><td>Buy Transaction</td><td>44</td><td>2.0700 USD</td></tr><tr><td> Common</td><td>Buy Transaction</td><td>525</td><td>2.0706 USD</td></tr><tr><td> Common</td><td>Buy Transaction</td><td>1</td><td>2.0708 USD</td></tr><tr><td> Common</td><td>Buy Transaction</td><td>60</td><td>2.0710 USD</td></tr><tr><td> Common</td><td>Buy Transaction</td><td>12</td><td>2.0717 USD</td></tr><tr><td> Common</td><td>Buy Transaction</td><td>57</td><td>2.0751 USD</td></tr><tr><td> Common</td><td>Buy Transaction</td><td>35</td><td>2.0789 USD</td></tr><tr><td> Common</td><td>Sell Transaction</td><td>1</td><td>2.0725 USD</td></tr><tr><td> Common</td><td>Sell Transaction</td><td>200</td><td>2.0750 USD</td></tr><tr><td> Common</td><td>Sell Transaction</td><td>5</td><td>2.0780 USD</td></tr><tr><td> Common</td><td>Sell Transaction</td><td>32</td><td>2.0800 USD</td></tr><tr><td> Common</td><td>Sell Transaction</td><td>3</td><td>2.0900 USD</td></tr></tbody></table></div>Ap29(b) Cash-settled derivative transactions<div><table><tbody><tr><td>Class of relevant security</td><td> Common</td></tr><tr><td>Product description e.g. CFD</td><td>CFD</td></tr><tr><td>Nature of dealing e.g. opening/ closing a long/ short position, increasing/ reducing a long/ short position</td><td>Closing short position</td></tr><tr><td>Number of reference securities (Note 6)</td><td>23</td></tr><tr><td>Price per unit (Note 5)</td><td>2.0800 USD</td></tr></tbody></table></div>(c) Stock-settled derivative transactions (including options)(i) Writing, selling, purchasing or varying<ul><li>Class of relevant security</li><li>Product description e.g. call option</li><li>Writing, purchasing, selling, varying etc.</li><li>Number of securities to which option relates (Note 6)</li><li>Exerciseprice per unit</li><li>Type e.g. American, Europeanetc.</li><li>Expiry date</li><li>Option moneypaid/ received per unit</li></ul>(ii) Exercise<ul><li>Class of relevant security</li><li>Product description e.g. call option</li><li>Exercising/ exercised against</li><li>Number of securities</li><li>Exercise price per unit (Note 5)</li></ul>(d) Other dealings (including transactions in respect of new securities) (Note 3)<ul><li>Class of relevant security</li><li>Nature of dealing e.g. subscription, conversion, exercise</li><li>Details</li><li>Price per unit (if applicable) (Note 5)</li></ul>Ap304. OTHER INFORMATION(a) Indemnity and other dealing arrangements<ul><li>Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer.Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state &#34;none&#34;</li><li>None</li></ul>(b) Agreements, arrangements or understandings relating to options or derivatives<ul><li>Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.</li><li>None</li></ul>(c) Attachments<ul><li>Is a Supplemental Form 8 attached?</li><li>YES</li></ul><div><table><tbody><tr><td>Date of disclosure</td><td>23 September 2025</td></tr><tr><td>Contact name</td><td>Paula Santos</td></tr><tr><td>Telephone number</td><td>020 7645 9700</td></tr></tbody></table></div>Public disclosures under Rule 8.3 of the Rules must be made to a Regulatory Information Service.Ap32SUPPLEMENTAL FORM 8IRISH TAKEOVER PANELDISCLOSURE UNDER RULE 8.1, RULE 8.3, RULE 38.5(b) ANDRULE 38.6 OF THE IRISH TAKEOVER PANEL ACT, 1997,TAKEOVER RULES, 2022DETAILS OF OPEN STOCK-SETTLED DERIVATIVE (INCLUDINGOPTION) POSITIONS, AGREEMENTS TO PURCHASE OR SELL ANDRIGHTS TO SUBSCRIBE FOR NEW SECURITIES1. KEY INFORMATION<div><table><tbody><tr><td>Full name of person making disclosure:</td><td>Citadel Group</td></tr><tr><td>Name of offeror/offeree in relation to whose relevant securities the disclosure relates:</td><td>MURAL ONCOLOGY PLC</td></tr></tbody></table></div>2. STOCK-SETTLED DERIVATIVES (INCLUDING OPTIONS)<div><table><tbody><tr><td>Class of relevant security</td><td>Product description e.g. call option</td><td>Written or purchased</td><td>Number of securities towhich optionor derivative relates</td><td>Exercise price per unit</td><td>Type e.g. American, European etc.</td><td>Expiry date</td></tr><tr><td>Common</td><td>Call Option</td><td>Purchased</td><td>900</td><td>5.0 USD</td><td>American</td><td>20/03/2026</td></tr><tr><td>Common</td><td>Call Option</td><td>Purchased</td><td>2,000</td><td>7.5 USD</td><td>American</td><td>20/03/2026</td></tr><tr><td>Common</td><td>Call Option</td><td>Purchased</td><td>8,700</td><td>2.5 USD</td><td>American</td><td>20/03/2026</td></tr><tr><td>Common</td><td>Call Option</td><td>Purchased</td><td>800</td><td>5.0 USD</td><td>American</td><td>19/12/2025</td></tr><tr><td>Common</td><td>Put Option</td><td>Purchased</td><td>-80,700</td><td>2.5 USD</td><td>American</td><td>15/01/2027</td></tr><tr><td>Common</td><td>Put Option</td><td>Purchased</td><td>-3,100</td><td>2.5 USD</td><td>American</td><td>19/12/2025</td></tr><tr><td>Common</td><td>Put Option</td><td>Sold</td><td>1,000</td><td>2.5 USD</td><td>American</td><td>17/10/2025</td></tr><tr><td>Common</td><td>Call Option</td><td>Sold</td><td>-43,400</td><td>2.5 USD</td><td>American</td><td>15/01/2027</td></tr><tr><td>Common</td><td>Call Option</td><td>Sold</td><td>-49,100</td><td>5.0 USD</td><td>American</td><td>15/01/2027</td></tr><tr><td>Common</td><td>Call Option</td><td>Sold</td><td>-7,000</td><td>2.5 USD</td><td>American</td><td>19/12/2025</td></tr></tbody></table></div>3. AGREEMENTS TO PURCHASE OR SELLFull details should be given so that the nature of the interest or position can be fully understood:Ap334. RIGHTS TO SUBSCRIBE FOR NEW SECURITIES (INCLUDING DIRECTORS' AND OTHER EMPLOYEE OPTIONS)<ul><li>Class of relevant security in relation to which subscription right exists:</li><li>Details, including nature of the rights concerned and relevant percentages:</li></ul>It is not necessary to provide details on a Supplemental Form with regard to cash-settled derivatives.The currency of all prices and other monetary amounts should be stated.For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.References in these notes to &#34;the Rules&#34; are to the Irish Takeover Panel Act, 1997, Takeover Rules, 2022.This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END ITPPKNBKDBKDNCB</div></div>

MURA

Citadel Group disclosed its position regarding Mural Oncology PLC under Rule 8.3 of the Irish Takeover Panel. As of September 22, 2025, Citadel holds 1.55% of Mural's relevant securities, including 255,172 shares and various derivatives. The disclosure includes details of recent transactions, with multiple purchases and sales of common stock. The announcement was made on September 23, 2025, and is part of compliance with takeover regulations.

REG - Citadel Group Mural Oncology PLC - Form 8.3 - Mural Oncology plc